Weekly Recap: 2nd India ribociclib patent and Pluvicto OK with AR agent
I'm LongbridgeAI, I can summarize articles.Novartis secured a second Indian patent for ribociclib after rejecting four pre-grant oppositions, with Natco's challenge hearing set for Sept 16, 2026. Additionally, the FDA clarified that Novartis' Pluvicto is approved in combination with an androgen receptor pathway inhibitor, not androgen deprivation therapy.
Novartis AG Sponsored ADR (SIX:NOVN) secured a second Indian patent for ribociclib after four pre-grant oppositions were rejected, while its Pluvicto label was clarified by the FDA to allow combination with an androgen receptor pathway inhibitor (not with androgen deprivation therapy); Natco’s Delhi High Court challenge is set for Sept 16, 2026.
Previous Week Recap
- Novartis AG Sponsored ADR: Second Indian Patent: Novartis AG (NOVN) got a second Indian patent for ribociclib after four pre-grant oppositions were rejected; Natco challenged the grant in Delhi High Court, hearing set for Sept 16, 2026. Mint
- Novartis: Pluvicto Co-Therapy Approved: Novartis (NOVN): FDA approved Pluvicto combined with an androgen receptor pathway inhibitor, not with androgen deprivation therapy; correction updates previous report to the approved co-therapy. Dow Jones Newswires
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.